New Delhi, May 20: Glenmark Pharmaceuticals Ltd on Friday said its US arm has received final approval from the US health regulator for its generic version of Abiraterone Acetate tablets used for the treatment of prostate cancer.

The approval granted by the US Food and Drug Administration (USFDA) to Glenmark Pharmaceuticals Inc, USA (Glenmark) is for Abiraterone Acetate tablets of strength 500 mg, the company said in a statement.

Also Read | COVID-19 Vaccine Update: Bharat Biotech's COVAXIN Gets Emergency Use Listing Approval From WHO

It is the generic version of Zytiga tablets, 500 mg, of Janssen Biotech Inc, it added.

Citing IQVIA sales data for the 12 month period ended March 2022, the company said Zytiga tablets 500 mg achieved annual sales of approximately USD 260.2 million.

Also Read | Twitter Rolls Out New Policy To Hide Tweets With Misinformation During Crisis.

Glenmark said its current portfolio consists of 173 products authorised for distribution in the US marketplace and 49 abbreviated new drug applications pending approval with the USFDA.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)